Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

✍ Scribed by Jian-quan Zhu; Wen-zhao Zhong; Guo-chun Zhang; Rong Li; Xu-chao Zhang; Ai-lin Guo; Yi-fang Zhang; She-juan An; Tony S. Mok; Yi-long Wu

• Book ID: 116334734
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 801 KB
• Volume: 265
• Category: Article
• ISSN: 0304-3835
• DOI: 10.1016/j.canlet.2008.02.064